in Dr Armaghani's view, "practice-changing," and perhaps most importantly by the consolidation of a new clinical category, HER2-low, which represents a more nuanced picture in the treatment of metastatic breast
It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation, the FDA said on Friday. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test. "This class of drugs has been used to...
Food & Drug Administration (FDA) approved Faslodex, or fulvestrant, for the treatment of hormone receptor positive metastatic breast cancer in post-menopausal women whose disease progresses following anti-estrogen therapy. Way that estrogen can stimulate the growth of tumors; Effectiveness of the drug;...
Breast cancer is the most common cancer in women in the U.S., excludingskin cancers, and is the second leading cause of cancer death in women, though deaths have steadily declined due to earlier detection through screenings and better treatment options. The earlier breast cancer is detected, ...
Paper presented at: 2019 San Antonio Breast Cancer Symposium; December 10-14; San Antonio, TX. Abstract GS1-02. Guidance for industry. Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. FDA website. ...
Researchers at Karolinska Institutet have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not. The cell-based method has been tested on patients with promising results, ac
被引量: 0发表: 2022年 Safety and aesthetic outcomes of double purse-string suture nipple reconstruction in early breast cancer patients undergoing nipple resection and endoscopi... However, double pursestring suture (DPS) shows promise in the treatment of nipple excision. This study aimed to inves...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapi...
The New Front in Breast Cancer: After Treatment Ends.The article discusses issues that plague breast-cancer victims after their treatment has ended. Survey data showed almost 90% of respondents suffered from one or more physical or psychological problems such as fatigue, sexual dysfunction, or ...
Approximately 10 to 15 percent of breast cancer cases do not respond to treatment with hormone therapy, which means that they are more aggressive and often recur. An international research team led by researchers at Lund University in Sweden has uncovere